Literature DB >> 24903481

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.

C Fernández-Rodríguez1, B Bellosillo2, M García-García3, B Sánchez-González4, E Gimeno4, M C Vela3, S Serrano3, C Besses4, A Salar4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24903481     DOI： 10.1038/leu.2014.184

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.

Authors:  Elodie Bohers; Sylvain Mareschal; Abdelilah Bouzelfen; Vinciane Marchand; Philippe Ruminy; Catherine Maingonnat; Anne-Lise Ménard; Pascaline Etancelin; Philippe Bertrand; Sydney Dubois; Marion Alcantara; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Genes Chromosomes Cancer       Date:  2013-11-05       Impact factor: 5.006

3.  High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.

Authors:  W Kraan; M van Keimpema; H M Horlings; E J M Schilder-Tol; M E C M Oud; L A Noorduyn; P M Kluin; M J Kersten; M Spaargaren; S T Pals
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

4.  Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry.

Authors:  A D G Krol; S le Cessie; S Snijder; J C Kluin-Nelemans; P M Kluin; E M Noordijk
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

5.  MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.

Authors:  Jung-Woo Choi; Younghye Kim; Ju-Han Lee; Young-Sik Kim
Journal:  Hum Pathol       Date:  2013-02-04       Impact factor: 3.466

6.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authors:  Guang Yang; Yangsheng Zhou; Xia Liu; Lian Xu; Yang Cao; Robert J Manning; Christopher J Patterson; Sara J Buhrlage; Nathanael Gray; Yu-Tzu Tai; Kenneth C Anderson; Zachary R Hunter; Steven P Treon
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

7.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

Review 8.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

9.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

10.  Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Authors:  Alberto Gonzalez-Aguilar; Ahmed Idbaih; Blandine Boisselier; Naïma Habbita; Marta Rossetto; Alice Laurenge; Aurélie Bruno; Anne Jouvet; Marc Polivka; Clovis Adam; Dominique Figarella-Branger; Catherine Miquel; Anne Vital; Hervé Ghesquières; Rémy Gressin; Vincent Delwail; Luc Taillandier; Olivier Chinot; Pierre Soubeyran; Emmanuel Gyan; Sylvain Choquet; Caroline Houillier; Carole Soussain; Marie-Laure Tanguy; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan
Journal:  Clin Cancer Res       Date:  2012-07-26       Impact factor: 12.531
View more
  16 in total

Review 1.  MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.

Authors:  Miguel Alcoceba; María García-Álvarez; Alejandro Medina; Rebeca Maldonado; Verónica González-Calle; María Carmen Chillón; María Eugenia Sarasquete; Marcos González; Ramón García-Sanz; Cristina Jiménez
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.

Authors:  A J Novak; Y W Asmann; M J Maurer; C Wang; S L Slager; L S Hodge; M Manske; T Price-Troska; Z-Z Yang; M T Zimmermann; G S Nowakowski; S M Ansell; T E Witzig; E McPhail; R Ketterling; A L Feldman; A Dogan; B K Link; T M Habermann; J R Cerhan
Journal:  Blood Cancer J       Date:  2015-08-28       Impact factor: 11.037

3.  High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment.

Authors:  Sisi Yu; Huaichao Luo; Meiling Pan; Luis Angel Palomino; Xiaoyu Song; Ping Wu; Jian-Ming Huang; Zhihui Zhang
Journal:  Oncol Lett       Date:  2017-11-22       Impact factor: 2.967

Review 4.  Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?

Authors:  Amit Dipak Amin; Tara L Peters; Lingxiao Li; Soumya Sundara Rajan; Ramesh Choudhari; Soham D Puvvada; Jonathan H Schatz
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-05

5.  Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.

Authors:  Ju-Han Lee; Hoiseon Jeong; Jung-Woo Choi; HwaEun Oh; Young-Sik Kim
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

6.  Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.

Authors:  Darius Juskevicius; David Jucker; Dirk Klingbiel; Christoph Mamot; Stephan Dirnhofer; Alexandar Tzankov
Journal:  J Hematol Oncol       Date:  2017-03-17       Impact factor: 17.388

7.  Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.

Authors:  Patrizia Mondello; Enrico Derenzini; Zahra Asgari; John Philip; Elliott J Brea; Venkatraman Seshan; Ronald C Hendrickson; Elisa de Stanchina; David A Scheinberg; Anas Younes
Journal:  Oncotarget       Date:  2017-02-21

8.  Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.

Authors:  Patricia Johansson; Ludger Klein-Hitpass; Florian Grabellus; Georg Arnold; Wolfram Klapper; Roman Pförtner; Ulrich Dührsen; Anja Eckstein; Jan Dürig; Ralf Küppers
Journal:  Oncotarget       Date:  2016-09-20

9.  Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.

Authors:  Yang Cao; Tao Zhu; Peiling Zhang; Min Xiao; Shuhua Yi; Yan Yang; Qinlu Li; Shaoping Ling; Yafei Wang; Lili Gao; Li Zhu; Jue Wang; Na Wang; Liang Huang; Peihong Zhang; Qiongli Zhai; Lugui Qiu; Jianfeng Zhou
Journal:  Oncotarget       Date:  2016-12-13

10.  DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.

Authors:  Xuemin Xue; Wenting Huang; Tian Qiu; Lei Guo; Jianming Ying; Ning Lv
Journal:  BMC Cancer       Date:  2020-08-27       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.